156 related articles for article (PubMed ID: 8241527)
1. Double-blind crossover study of ranitidine and ebrotidine in gastro-esophageal reflux disease.
Sito E; Thor PJ; M[aczka M; Lorens K; Konturek SJ; Maj A
J Physiol Pharmacol; 1993 Sep; 44(3):259-72. PubMed ID: 8241527
[TBL] [Abstract][Full Text] [Related]
2. Oesophageal function after oral ranitidine: an acute double blind study in normal subjects.
Baldi F; Ferrarini F; Balestra R; Borioni D; Brunetti G; Barbara L
Hepatogastroenterology; 1984 Feb; 31(1):38-40. PubMed ID: 6321311
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of esophageal manometry and gastroesophageal pH monitoring for responsiveness of reflux disease to medical therapy in children.
Cucchiara S; Campanozzi A; Greco L; Franco MT; Emiliano M; Alfieri E; Calabrese F; Numeroso V
Am J Gastroenterol; 1996 Apr; 91(4):680-5. PubMed ID: 8677928
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of ebrotidine compared with ranitidine in patients with duodenal ulcer.
Gabryelewicz A; Konturek SJ; Butruk E; Dzieniszewski J; Marlicz K; Nowak A; Torres J; Marquez M; Ortiz JA
Eur J Gastroenterol Hepatol; 1995 Apr; 7(4):361-6. PubMed ID: 7600143
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of ebrotidine and ranitidine in the treatment of benign gastric ulcer.
Gedliczka O; Bobrzynski A; Rembiasz K; Fillat O; Torres J; Herrero E; Márquez M; Camps F; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):560-4. PubMed ID: 9205765
[TBL] [Abstract][Full Text] [Related]
6. [Postoperative evaluation of esophageal mucosal change dynamics in patients with reflux diseases].
Wallner G; Misiuna P; Chibowski D; Polkowski W; Abramowicz K; Sory A
Wiad Lek; 1997; 50 Suppl 1 Pt 1():273-81. PubMed ID: 9446369
[TBL] [Abstract][Full Text] [Related]
7. Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat.
Palop D; Agut J; Márquez M; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):439-46. PubMed ID: 9205740
[TBL] [Abstract][Full Text] [Related]
8. Ebrotidine versus ranitidine in the treatment of acute duodenal ulcer. A multicentre, randomized, double-blind, controlled clinical trial.
Matov V; Metchkov G; Krastev Z; Tchernev K; Mitova R; Márquez M; Torres J; Herrero E; Fillat O; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):555-9. PubMed ID: 9205764
[TBL] [Abstract][Full Text] [Related]
9. Ebrotidine versus ranitidine in the healing and prevention of relapse of duodenal ulcer. A multicentre, double-blind, parallel, randomized, controlled study.
Tulassay Z; Döbrönte Z; Farkas I; Juhász L; Simon L; Prónai L; Torres J; Márquez M
Arzneimittelforschung; 1997 Apr; 47(4A):551-5. PubMed ID: 9205763
[TBL] [Abstract][Full Text] [Related]
10. pH, healing rate, and symptom relief in patients with GERD.
Huang JQ; Hunt RH
Yale J Biol Med; 1999; 72(2-3):181-94. PubMed ID: 10780580
[TBL] [Abstract][Full Text] [Related]
11. Gastric acid inhibitory profile of ebrotidine, a novel H2-receptor antagonist in humans.
Maczka M; Kwiecień N; Obtułowicz W; Konturek SJ; Kamiński K; Oleksy J; Gabryelewicz A; Torres J
J Physiol Pharmacol; 1992 Jun; 43(2):139-48. PubMed ID: 1356519
[TBL] [Abstract][Full Text] [Related]
12. Ranitidine therapy for gastroesophageal reflux disease. Results of a large double-blind trial.
Sontag S; Robinson M; McCallum RW; Barwick KW; Nardi R
Arch Intern Med; 1987 Aug; 147(8):1485-91. PubMed ID: 3307670
[TBL] [Abstract][Full Text] [Related]
13. [The effect of Nissen-Rossetti fundoplication on the motor function of swallowing in patients with reflux diseases].
Wallner G; Misiuna P; Dabrowski A; Abramowicz K; Polkowski W; Mijal M
Wiad Lek; 1997; 50 Suppl 1 Pt 1():282-92. PubMed ID: 9446370
[TBL] [Abstract][Full Text] [Related]
14. Relationship of severity of gastroesophageal reflux disease with gastric acid secretory profile and esophageal acid exposure during nocturnal acid breakthrough: a study using 24-h dual-channel pH-metry.
Ghoshal UC; Chourasia D; Tripathi S; Misra A; Singh K
Scand J Gastroenterol; 2008; 43(6):654-61. PubMed ID: 18569981
[TBL] [Abstract][Full Text] [Related]
15. Duodenogastroesophageal reflux: results of medical treatment and antireflux surgery.
Elhak NG; Mostafa M; Salah T; Haleem M
Hepatogastroenterology; 2008; 55(81):120-6. PubMed ID: 18507090
[TBL] [Abstract][Full Text] [Related]
16. Esophageal mucosal eicosanoids in gastroesophageal reflux disease and Barrett's esophagus.
Triadafilopoulos G; Kaczynska M; Iwane M
Am J Gastroenterol; 1996 Jan; 91(1):65-74. PubMed ID: 8561146
[TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists.
Martínez C; Albet C; Agúndez JA; Herrero E; Carrillo JA; Márquez M; Benítez J; Ortiz JA
Clin Pharmacol Ther; 1999 Apr; 65(4):369-76. PubMed ID: 10223772
[TBL] [Abstract][Full Text] [Related]
18. Gastroprotective and ulcer-healing activities of a new H2-receptor antagonist: ebrotidine.
Brzozowski T; Majka J; Konturek SJ
Digestion; 1992; 51(1):27-36. PubMed ID: 1353465
[TBL] [Abstract][Full Text] [Related]
19. Effect of ebrotidine on ethanol-induced gastric mucosal damage in the rat. Comparative study with other H2-receptor antagonists.
Palop D; Romero A; Villamayor F; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):450-4. PubMed ID: 9205742
[TBL] [Abstract][Full Text] [Related]
20. Gastroprotective properties of ebrotidine. A review.
Slomiany BL; Piotrowski J; Slomiany A
Arzneimittelforschung; 1997 Apr; 47(4A):459-67. PubMed ID: 9205744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
